Credit rating agency A.M. Best Co. affirmed the issuer credit
rating (ICR) of
Coventry Health Care Inc.
) at "bbb-". The rating agency also reiterated all the debt ratings
of the company.
Additionally, A. M. Best raised the financial strength rating
(FSR) of Coventry's subsidiaries - Coventry Health Care of Iowa
Inc. and Coventry Health Care of Illinois Inc. - to "A-" from "B++"
and the ICR of the subsidiaries to "a-" from "bbb+". The rating
agency also raised the FSR of two other subsidiaries - Coventry
Health Care of Louisiana Inc. and Coventry Health Care of Delaware
Inc. - to "A-" from B+" and their ICRs to "a-" from "bbb-".
The FSR and ICR of Coventry Health Care of Kansas Inc. were also
raised to "A-" and "a-" from "B++" and "bbb", respectively. A. M.
Best also raised the FSR of three other subsidiaries - Coventry
Health Care of Florida Inc., Coventry Health Plan of Florida Inc.
and Coventry Summit Health Plan Inc. - to "B+" from "B" and ICR to
"bbb-" from "bb-".
Enhanced operating efficiency and expanding membership base of
another subsidiary, HealthCare USA of Missouri LLC, led to
reaffirmation of its FSR at "B++" and upgradation of its ICR to
"bbb+" from "bbb". Meanwhile, improved underwriting trend and
satisfactory capitalization of OmniCare Health Plan Inc. prompted
A. M. Best to upgrade the subsidiary's FSR to "B++" from "B+" and
ICR to "bbb" from "bbb-".
A. M. Best has a stable outlook on all the ratings, indicating
low possibility of any rating change in the near term.
Earlier this week, Coventry cancelled its agreement with
) to provide coverage for the latter's MaterniT21 PLUS test to its
2.2 million policyholders. Sequenom's subsidiary, Sequenom Center
for Molecular Medicine LLC, had signed a provider network
participation agreement with Coventry on May 4, 2012,
effective July 1, 2012.
However, on May 14, 2012, Coventry cancelled the agreement
without citing any reason. The company will stop its overage of
Sequenom's tests from August 31, 2012.
Coventry currently carries a Zacks #5 Rank, which translates
into a short-term 'Strong Sell' rating.
COVENTRY HLTHCR (CVH): Free Stock Analysis
SEQUENOM INC (SQNM): Free Stock Analysis Report
To read this article on Zacks.com click here.